RecruitingPhase 2NCT05557578

GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence

Studying Cholangiocarcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Zhejiang Cancer Hospital
Principal Investigator
Yuhua - Zhang, M.D.
Zhejiang Cancer Hospital
Intervention
Tislelizumab combined with GEMOX (GOT) regimen(drug)
Enrollment
20 enrolled
Eligibility
18-75 years · All sexes
Timeline
20232025

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05557578 on ClinicalTrials.gov

Other trials for Cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Cholangiocarcinoma

← Back to all trials